Hi, everyone. My name is Maury Raycroft. I am one of the biotech analysts at Jefferies. I would like to welcome the Enliven management team. We have Rick Fair, the CEO, and Ben Hohl, the CFO. Thanks so much for joining us today.
Thank you, Maury.
We will do a fireside chat format. Maybe for those who are new to the story, if you can give a one-minute intro to the company.
Sure. Thanks, Maury and the Jefferies team, for having us. We appreciate being here. Enliven is a company that focuses on developing better molecules against known biology. Our lead program is relcobatinib, or ELVN-001, which is a BCR-ABL1 TKI being developed in CML. We are initiating our first phase III trial in second-line plus CML patients imminently. Committed to starting that study before year-end, and it is November 17th by last count, so we are right on top of it. We have a pipeline asset in Graves' disease. We expect to be able to communicate more about that as we get closer to IND in 2027.
Got it. Yeah, that's a great intro. You mentioned the phase III study, which was the first question I was going to ask about. We're not seeing anything posted on ct.gov yet for the study. Can you say how far along you are with site selection and contracting, and when do you expect the first sites to be activated?
I can say we have sites activated, and the posting should be on ClinicalTrials.gov. If it's not, that's surprising and news. I'll need to follow up on that. We have identified approximately 180 sites globally for the study. We are in the process of contracting and going through IRB reviews in those sites and expect to have all of them activated at some point in 2027, but we'll start trial accrual imminently. Expect about an 18-month trial accrual based on what we're hearing from sites and triangulating with other CML studies, such that we could have a top-line readout as early as early 2029.
Got it. So for starting the study, I guess, it sounds like you're pretty far along with the process already. Starting the study would be dosing that first patient. Is that how you look at it, or?
Yeah, I would say screening and dosing, yeah.
Yeah. Okay. You mentioned the 18 months timeline to enroll. In the past, you've also said about 90 sites potentially. Wondering if that's still the case, and how many sites you think you would need to-.
Yeah. We have about 180 sites globally.
Okay.
About 2x that.
Okay.
Expect to have those open at various times based on various health authority timelines, but by the second half of 2027, have all of those on board.
Got it. Okay. For enrollment by geographic region, I guess, how many patients do you anticipate could come from the U.S. versus ex-U.S.?
Yeah, I wouldn't try to forecast that now, but I would say, just based on site selection, 1/4 to 1/3 in the U.S., majority, more than half in Europe, and then the remainder coming out of Asian countries, including Japan, South Korea, Taiwan, Singapore.
Got it. Okay. For the phase III, the control arm is investigator choice. What are your latest expectations on MMR rates that you're assuming at weeks 24 and 96 for the control arm? How much additional MMR improvement do you expect for relcobatinib versus the second-gen TKIs over that period?
Yeah, so the study's randomized our drug against physicians' choice of second-generation TKIs, dasatinib, nilotinib, or bosutinib. As you probably know, there's a lot of heterogeneity in the datasets that have been reported for those drugs and MMR rates in various lines of therapy. I'd say that the most reliable dataset we have is the bosutinib dataset as the control arm in the ASCEMBL trial, ASCEMBL's pivotal third-line plus trial. When we do cross-trial comparisons of our drug to bosutinib in that study in third, fourth, and fifth-line plus patients, we see a 20 to 30-point MMR improvement. That said, we don't have much data in second-line patients to go on, and that will be part of our pivotal study.
We've also heard from investigators that the performance of second-generation TKIs has improved over time since the time of the ASCEMBL study, because physicians have grown more comfortable managing adverse events through dose management. Given those uncertainties, we decided to be more conservative, and instead of banking the 20%-30% improvement, we've powered the study to detect a minimum detectable difference of 10 percentage points, which is a clinically meaningful improvement. That's how we got to our 450-patient study. Our most important priority was to have a positive study regardless of the uncertainty in performance in second line, so we decided to be more conservative and spend a few extra months accruing some extra patients just to be sure.
Got it. Yeah, that makes sense. For SCEMBLIX in the control arm, have you decided if you would cap SCEMBLIX use in the control arm?
I think there'll be no SCEMBLIX in the control arm. Trick question there. Again, we're randomizing to second-generation TKIs, so nilotinib, bosutinib, or dasatinib.
Okay.
So no SCEMBLIX use there. One question we get a lot about SCEMBLIX is in terms of whether we're capping or pre-specifying previous SCEMBLIX use.
Right.
In other words, patients enrolling in the study, do they have to have been on SCEMBLIX? Can they have never had SCEMBLIX? We will take an all-comer second-line plus population, so they could have had SCEMBLIX in previous lines. We are not a priori specifying what proportion will have had SCEMBLIX previously. Based on our phase I experience, we are seeing about 70% of the patients enrolling in our phase I study have seen SCEMBLIX at some prior line of therapy. We think that is potentially predictive of what we will see in phase III, but we will take all comers.
Got it. Okay. How did you incorporate crossover and treatment discontinuations into the week 96 powering assumptions?
Yeah, so we get asked the question a lot. I know for many oncology drug developers, the idea of crossover in a cancer study makes people nervous. This is not a time-to-event study where we are using a PFS surrogate with an OS final. The trial design is primary endpoint of 24-week major molecular response, confirmed at 96 weeks. Under our definitions of response, patients who have not responded at 24 weeks and discontinue due to efficacy are eligible to crossover to relcobatinib if they choose to from the control arm. But they will still be considered a treatment failure at 96 weeks because they failed to respond to their initial treatment. So, consider that almost like a compassionate use or off-study use of that. So it does not really affect the efficacy analysis either at 24 or at 96 weeks.
Got it. Okay. Makes sense. Have you engaged with the EMA or other ex-U.S. regulators on the phase III design, particularly the control arm, the endpoint, and the statistical analysis plan?
Yes. We got CHMP scientific advice and have submitted a protocol through the clinical trial protocol framework. We recently had a pre-PMDA meeting with Japan Health Authority, so we're in the process of getting other health authority feedback, but feel like we've had a good dialogue with Europe and are comfortable with our trial design based on their input.
Got it. Of the three stratification factors, you mentioned the prior asciminib and y ou've also mentioned the BCR-ABL1 above 10%. And just being the second-line patients as well. Are any of them pre-specified and alpha-controlled for standalone results?
No.
Okay. Yeah.
Our view was that the stratification factors of baseline transcript level and prior number of TKIs was important because those are predictors of response. The FDA also asked us to include prior asciminib use as a stratification factor, which we found a little confusing because our data suggests prior asciminib use has no bearing on the responses that we see with relcobatinib, but we did it at their request.
Got it. Okay. Merck's presenting updated phase I/II data for their drug at ASH in December. The abstract reported 54% week 24 MMR, down from the ASH 2025 data, and consistent with the decline disclosed in the acquisition proxy, which suggests to us it could reflect greater enrollment of the SCEMBLIX-experienced patients. What are you most focused on in the Merck's data update that can inform Enliven's competitive positioning, or is the more important read-through MRL's phase III design and development, the Merck phase III design and development timelines?
Yeah. I'd say that abstract raises more questions for us than answered them to some degree. I think as you point out, relative to the ASH presentation of TERN-701 last year, MMR achieved rates have declined and now look approximately like what we're seeing with our 80 milligram dose. That said, there are a few caveats with that. One of the things we know predicts phase I MMR achieved rates is the maturity of the data. We've discussed this ad nauseum, and I hate to bore you with it, Maury, but in an MMR achieved by 24 weeks analysis, which is the standard in phase I, you count patients who respond early at any time prior to 24 weeks, you count early discontinuations, and you count any patient who's past 24 weeks in that calculation. You exclude patients who are less than 24 weeks who have not responded.
So you're basically discarding a bunch of early non-responders who are going to turn into late non-responders and be added to the denominator later. So we know from looking at our data, we know from looking at Terns's data, as data matures and you get all your patients past 24 weeks and can do a landmark at 24-week analysis, which is what's used in registrational trials, that your MMR rates come down. So we thought when we saw the abstract, "Aha, it fell from 75% at the high dose in their ASH from 2025 to 54%." This is their data maturing. What's curious is that their data set in their abstract is actually less mature than the one they presented at ASH last year. So that suggests they will see further declines from the 54% as their data mature.
I think the median follow-up at ASH 2025 was about six months or 6.1 months. It's now fallen to five because they enrolled a bunch of patients in the time between those data cuts. So that's a little confusing. I think the other confusing bit is that Merck changed the way they're calculating MMR relative to the way that Terns did. They highlighted in their abstract that they excluded from their MMR efficacy analysis patients who had myristoyl pocket mutations. So these are patients who failed, presumably, asciminib due to efficacy because they developed a resistance mutation to it. So they're discarded completely from the analysis. We know in ASH 2025, Terns had a very small number of those patients. I think six is what they identified, patients who had been on asciminib and failed. But at least they calculated them in the analysis.
In this case, they're discarding them, which is definitely not standard. I think reinforces our positioning that for patients who fail asciminib, going to the best ATP-competitive inhibitor, namely RELKO, will be the logical choice. Merck is, I think, somewhat ceding that ground by saying, "We're not even going to count them because we won't work there.
Yeah. Yeah, makes sense.
Curious.
Yeah. It'll be interesting to see what they show in the data. For SCEMBLIX-experienced patients, you mentioned you basically see the same results for RELKO, whether they have asciminib or not.
Yep.
As you enroll more patients, do you think that'll hold up or?
Yeah. Yeah, I mean, mechanistically, there's no reason why a patient who's developing resistance to asciminib would be resistant to our drug. I think when you look at our patients by line of therapy, as we broke out in our presentation around EHA, you see the exact same response rates by line of, essentially the same response rates by line of therapy, whether you've had the asciminib before or not. That makes sense to us.
Yeah. Okay. With Merck advancing the higher 500 milligram dose into its pivotal cohort, if the updated second-line plus data shows a meaningful dose response versus 320 milligrams, would that change how you view Merck's competitive potential in frontline CML? Just with their 500 milligram dose that they're advancing.
Yeah, I mean, I think you have to look at the totality of the data. So, what is the efficacy and what is the safety? I think our thesis on the Merck molecule has always been that it is an experiment in high exposure SCEMBLIX. So it's an allosteric approach, binds the same way, and they just seem to be getting a higher exposure level than sort of standard dose SCEMBLIX. High-dose SCEMBLIX has been studied a lot by Novartis, and they launched the standard dose SCEMBLIX because high-dose SCEMBLIX was mildly more effective, but also more toxic.
Right.
I think they chose the lower dose for that reason, saving the higher dose for certain patients who need it, like T315I mutants. I think our expectation would be the more you push the dose of the Merck molecule, the more you'll see maybe very small increments of efficacy, but more lipase increases, myalgias, and aches and pains that cause discontinuations, potentially heme tox, potentially hypertension, the class effects that you see with these BCR-ABL TKIs. So, I think we'll see if it becomes more competitive. I don't think it's a great trade-off in CML to push for a little bit more efficacy if you're going to get-.
Greater safety.
Higher safety liability. That's not how treatment decisions are made.
I'd also just note that there have been now two abstracts of Chinese frontline patients from Hansoh, which owns the molecule for development in China, and both of those point to the response rates that are very, very similar to SCEMBLIX.
Right. Yeah. All makes sense. For your phase I study, should we expect new data points next year? If so, what would you want to show to build out your value proposition for doctors and investors?
Yeah, I think we do plan to present an update on our phase I study at the kind of Q2 timeframe, mid-year next year. I think longer follow-up to show the durability of response, the continued excellent safety and tolerability profile will be useful. I think in light of the Merck data and the degradation they've seen in their efficacy, just showing that our efficacy rates are holding up over time would be differentiating and useful to show. But also to say maybe the last patient population where we really haven't presented much data is the T315I mutant population. It's a small population in today's CML market, but it is a little bit of a litmus test for potent efficacy.
It's taken us a long time to find any of them in our phase I study, but we do have some now, and we should be able to report on some preliminary results on that.
Got it. Would you show 48-week MMR at 80 milligrams and durability of achieved MMR in second-line-only patients?
We have very few second-line-only patients in our phase I study, so it'd be unlikely we show that broken out independently because this is such a small number of patients. It's a little hard to explain why that is. I mean, I guess they have many approved treatment options, so maybe getting enrolled in a phase I clinical trial isn't that useful. We wouldn't expect to enroll a lot from here because those are patients we prefer to have in our phase III. So, I think what we have is probably what we have, but we'll show the data that we have, but I think our study is almost exclusively a third-line plus study.
Yeah. Makes sense. For timing, I guess when could you do this data update? Would it be EHA 2027, or could you get an update earlier?
I think our focus would be in that timeframe, whether it's EHA, ASCO, or both.
Okay.
Timeframe we're talking about.
Okay. You're continuing to enroll patients in the phase I study to get a larger safety database with long follow-up, which could be sufficient to get alignment on a frontline pivotal without needing frontline data. Can you talk about whether you are enrolling certain patient subsets into this, or is it more of an all-comer-based population?
Yeah, as we sit here today, the patients that we are still enrolling in our study are patients who are second line, although again, we are not getting many of them, or patients with T315I mutations. We are in the process of preparing an amendment to amend the study to allow for frontline patients to be enrolled in that study. As you may know, we have had an interest in generating some frontline data just to start to evaluate the profile there as we prepare for a registrational trial in newly diagnosed patients. We previously agreed to sponsor an investigator-sponsored trial with a cooperative group. That has gone a little more slowly than we would like, so we have decided to add a cohort to our ongoing phase I study and expect to start enrolling those patients in 2027.
I think those are the patients that you will see continue to enroll in the study will be T315I mutants and newly diagnosed patients. As we open up the phase III study, all the second-line plus patients who are eligible for that study will go to the phase III.
Right. Makes sense. For the amendment going through, any perspective on timing on that?
We should be able to start enrolling in the early part of 2027.
Okay. You have discussed starting a phase I combo study with an allosteric inhibitor in 2027, aiming to get to deeper molecular responses and ultimately enable treatment-free remission. Presumably, it would start in later-line patients for dose optimization before moving into earlier lines to evaluate DMR. Can you walk through the clinical development plan there, including the target patient population and endpoints, and where discussions stand with the partner?
Yeah, I don't think we're ready to communicate a specific trial, but I think in concept what you just described is right, is we'll probably go to previously treated patients to evaluate safety and to get to dose of the two drugs together. I think once we have that, a small expansion in a more interesting patient population, potentially a little earlier in treatment, those are the patients who are aspiring for treatment for your deep response and treatment for remission. So a small expansion cohort there to evaluate preliminary efficacy, and then from there, we can decide. If we're seeing dramatically higher rates of DMR with acceptable tolerability trade-offs, then I think that could potentially lead to a registrational study. But that's two steps down the road. We'll start with safety and dose, as we always do.
Makes sense. Any gating factors to getting that study started?
Nope. Just gaining alignment with all involved and getting the protocol done and going. Our focus has obviously been on our phase III study. That's been the higher priority, so we'll get we'll turn to this as that gets up and running.
Right. For frontline CML, you plan to start a phase III in approximately 2028. Do you expect to have a sufficient clinical data set in 2027 to start discussions with FDA on the frontline pivotal trial, and when might you request that meeting?
Yeah. We did have an interaction with the FDA around ENABLE-2, our second-line plus study, but we asked the question about what would it take to get to a registrational trial in frontline. I think the good news was they really wanted to just to see longer follow-up of the patients we have at 80 milligrams QD. As you probably know, there's a history in this class, driven by ponatinib, where they approved drugs, then found out later they had some cardiovascular toxicities and were disappointed that they had let them into early-line patients too soon. I think they now are looking for a decent-sized data set at a phase III dose out a year to sort of de-risk these things for potential cardiovascular tox.
We don't expect any unusual cardiovascular tox given the specificity of our molecule, but I think they want to see that data set. We'd expect that sometime mid-year next year, we have a data set adequate to have those conversations. That puts us on track for a start of a pivotal trial in the first half of 2028. But as we get closer to it, we'll guide more specifically the timeline.
Got it. It makes sense. You mentioned the IST study earlier. What are the gating factors to getting that study started? Is that going to be more likely first half of next year, or how should we think about timing?
Yeah. The previously described IST will be a phase II study done by a cooperative group. The timing is really driven by them, not us. As you know, with ISTs, that's a bit of the downside. But I'd expect them to start enrolling sometime mid-next year and have data to follow from there. Given that timeline, that's what encouraged us to start our own effort here. We think we can move a little faster and generate a little bit more data such that we might be reading out some first frontline data in 2028.
Got it. Okay. For Graves', you've said it's reasonable to assume a first-in-class oral once-daily molecule could reach the clinic in the first half of next year if successful. Have you nominated a development candidate, and are IND-enabling studies underway?
Yes. We'll talk more about this when we get to an IND, which we expect could happen in the first part of next year, and that's probably all I'll say about it today.
Okay. Okay. What would drive a go, no-go decision with this program, and when will you disclose the target for it?
As we get to IND clearance and are starting a healthy volunteer study, we'll talk more about it. We're not trying to be coy. I think this program's been in development at Enliven for a while. I think we had a previous development candidate that didn't make it through IND-enabling studies, so we're trying to be humble and make sure we have a clinical candidate before we get too far into it. We're really excited about the opportunity. We're making great progress. There's a lot of enthusiasm across the space for Graves' disease assets and a lot of interesting modalities and approaches to it today. We think a once-daily oral approach would be really attractive, and hope we can get there, and we'll talk to you about it early next year if we get there.
Makes sense. For potentially partnering on Graves', is that something that you're considering? I guess, would you do that earlier or want to get proof of concept based on that?
Never say never in anything, but I think our view is it doesn't require a lot of capital or very complicated studies to get to proof of concept in Graves' disease. You just need to show that you can regulate thyroid hormone levels. Given that it's a pretty straightforward surrogate and a pretty straightforward development path through that, I think we would probably want to get it to proof of concept before we evaluate offers for the asset.
Got it. Anything else that you're considering on the BD front at this point that you want to highlight?
Nothing to talk about today.
Okay. Is that something that is an important part of strategy going forward?
Yeah, I think as we build the company, I think our hands are pretty full right now with a multi-study registrational program in CML and an asset heading to the clinic in Graves' disease. As those things are in flight, building a pipeline behind it is going to be something we want to do, and we will take steps to do that as we get there.
Makes sense.
I am sure you will ask too, but our runway is also in cash into 2030, and I think we definitely want to make sure we maintain that so we have the runway through the second-line plus pivotal trial, because that is really important for us.
Right. Yeah. Makes sense. You want to see what the cash position is?
Yeah, $85 million.
Okay. Yeah. Maybe for the phase III study, as you get this up and running, I guess what kind of updates along the way are you going to provide to everyone?
I don't know. I mean, I guess we'll tell you how enrollment's going and if we have any material changes to our timing guidance. We said we'll approve the study in approximately 18 months. I think if we start to dramatically exceed or fall behind that, we would communicate that. But as you know, it's a phase III study. We'll probably tell you the answer when it's done.
Yeah.
And I think just also in terms of like the 001 updates, we talked about the multiple ways we will be generating the frontline data.
Yeah.
We know investors and BD is interested in seeing that. So, those will also come along the way as well.
Got it.
Yeah, there will still be a consistent data flow. There is not a lot to say about a phase III study other than, are you on track or are you not on track?
Yeah.
Our expectations will be on track.
Okay. Okay. Well, thanks so much for joining us today. It is great speaking with you.
Yeah. Thanks, Maury. Appreciate it.